Preparation method and application of polyamine derivative
By combining ligustrazine with cinnamic acid compounds with spermidine and spermine, a multifunctional neuroprotective drug was developed, which solved the problem of poor effectiveness of existing treatment methods and achieved neurodegenerative diseases and glycolipid metabolic properties Effective treatment of diseases.
Patent Information
- Application Number
- CN202410987879.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-23
- Publication Date
- 2024-12-06
AI Technical Summary
The existing treatment methods for neurodegenerative diseases are not effective and are accompanied by obvious adverse side effects, and there is a lack of effective neuroprotective drugs to alleviate the disease progression.
By splicing the citrus spirothazine in the traditional Chinese medicine citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citrus citru , neurodegenerative diseases and glycolipid metabolic diseases.
These derivatives show significant neuroprotective activity, which can effectively scavenge free radicals, inhibit inflammation and oxidative stress, improve cell survival and growth, and provide potential new drug options for treating neurodegenerative and glycolipid metabolic diseases.
Smart Images

Figure SMS_3 
Figure SMS_4 
Figure SMS_5
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of organic synthesis, and relates to eight multifunctional compounds with neuroprotective effects, their synthesis methods, pharmaceutical uses and applications in preventing or treating diseases. Background Art
[0002] Neurodegenerative diseases refer to diseases caused by abnormal death of central neurons, which leads to dysfunction of the nervous system. So far, there is no fundamental treatment that can slow the progression of the disease. Many neurodegenerative diseases are caused by proteins with unknown activity. Neurodegenerative diseases are disease states in which cells and neurons of the brain and spinal cord are lost. Cells of the brain and spinal cord generally do not regenerate, so excessive damage can be devastating and irreversible. Neurodegenerative diseases are caused by the loss of neurons or their myelin sheaths, which worsen over time to cause dysfunction. Neurodegenerative diseases are divided into two groups according to their phenotype: one affects movement, such as cerebellar ataxia; the other affects memory and related dementia. Currently, the more common diseases are Alzheimer's disease and Parkinson's syndrome. Neurodegenerative diseases have now become a serious health disease for the elderly, and the severity of the disease has become increasingly prominent with the aging process. At present, neurodegenerative diseases are mainly treated with drugs. Clinically, the main drugs for the treatment of neurodegenerative diseases are levodopa and anticholinergic drugs such as trihexyphenidyl, but the effects of these drugs are not ideal and are accompanied by more obvious adverse side effects. Neurodegenerative diseases have become a social problem and effective drugs are urgently needed for their treatment.
[0003] Neuroprotection is a measure that favorably improves the course of a disease or intervenes in the underlying pathogenesis, thereby producing lasting beneficial effects for the patient (WIENDL H, ELGER C, et al.Gaps Between Aims and Achievements in Therapeutic Modification of Neuronal Damage ("Neuroprotection") [J / OL]. Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics, 2015, 12 (2): 449-454. DOI: 10.1007 / s13311-015-0348-8.), effective neuroprotection leads to disease improvement. Neuroprotection can be achieved by direct action on neurons (primary neuroprotection) or by interfering with processes that lead to secondary cell death (such as inflammation, oxidative stress). It has been found that compounds isolated from natural plants, such as flavonoids, polyamines, and glycoside drugs, can have therapeutic effects on various diseases and brain diseases through neuroprotective effects. These neuroprotective effects are mainly due to the ability of these drugs to cross the blood-brain barrier, eliminate reactive oxygen species, and increase the concentration of neurotrophic factors (including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophic factors (NT-3, NT-4 / 5), etc.), and directly bind to the membrane receptors of these neurotrophic factors, regulate and activate signal cascades, and make neuronal cells plastic, survive, proliferate and grow, thereby achieving better learning, memory and growth ( TORNER L, FENTON NAVARROB. Polyphenols and Neurodegenerative Diseases: Potential Effects and Mechanisms of Neuroprotection [J / OL]. Molecules (Basel, Switzerland), 2023, 28(14): 5415. DOI: 10.3390 / molecules28145415.). In the treatment of neurodegenerative diseases, neuroprotection can not only be used as a single treatment method, but can also be combined with other treatment methods such as drug therapy, rehabilitation training, etc. to exert a synergistic effect and bring better efficacy and prognosis to patients. The research and application of neuroprotection is of great significance for the treatment of neurodegenerative diseases.
[0004] The polyamines putrescine, spermidine and spermine are very important polycations in mammalian cells. Their cellular levels are strictly regulated by degradation and synthesis as well as uptake and export. Under normal circumstances, the level of polyamines in the body gradually decreases with age. It is reported that in humans, increasing dietary spermidine intake is positively correlated with life expectancy (KiechlS, Pechlaner R, et al. Higher spermidine intake is linked to lower mortality: a prospective population-based study. Am J Clin Nutr. 2018Aug 1; 108(2): 371-380. doi: 10.1093 / ajcn / nqy102.). In humans, increased spermine (Soda K, Uemura T, et al. Polyamine-Rich Diet Elevates Blood Spermine Levels and Inhibits Pro-Inflammatory Status: An Interventional Study. Med Sci (Basel). 2021 Mar 29; 9 (2): 22. doi: 10.3390 / medsci9020022.) or spermidine (Schwarz C, Horn N, et al. Spermidine intake is associated with cortical thickness and hippocampal volume in older adults. Neuroimage. 2020 Nov 1;221:117132.doi:10.1016 / j.neuroimage.2020.117132.) was positively correlated with a reduction in inflammatory markers, an increase in cortical thickness and hippocampal volume, and improved cognitive performance, possibly because exogenous polyamine supplementation protects against cognitive decline by stimulating autophagy and mitophagy, improving mitochondrial respiration, and reducing neuroinflammation. Polyamines provide protection under conditions of oxidative stress, such as hypoxia, ischemia, and inflammation. They stimulate the expression of different factors in the antioxidant response, such as catalase and glutathione, and they also function as antioxidants themselves. Polyamines also have strong anti-inflammatory effects. In microglia, exogenous administration of spermidine can prevent the production of proinflammatory cytokines induced by lipopolysaccharide, the expression of inducible nitric oxide synthase and cyclooxygenase-2, and the activation of the NF-κB signaling pathway. In astrocytes, ATP13A2 induces excessive activation of NLRP3 inflammasomes, leading to astrocyte-induced neuroinflammation. Spermidine inhibits K+ Efflux channels indirectly inhibit the NLRP3 inflammasome. In a mouse model of accelerated aging, the addition of spermine and spermidine to drinking water downregulated the expression of NLRP3 and the proinflammatory cytokines IL-1β and IL-18.
[0005] Drugs used clinically to treat cerebrovascular diseases, such as ozagrel and cinnamic acid, contain cinnamic acid structures. Cinnamic acid compounds have become a hot topic for structural modification due to their drug-like properties and biological characteristics; the introduction of active phytochemical parts provides the potential to exert additive or synergistic effects to discover new derivatives with multiple effects (Zhang WX, Wang H, et al. Design, synthesis and biological evaluation of cinnamic acid derivatives with synergetic neuroprotection and angiogenesis effect. Eur J Med Chem. 2019 Dec 1; 183: 111695. doi: 10.1016 / j.ejmech.2019.111695.). Ligustrazine (TMP), or ligustrazine, is a compound derived from the traditional Chinese herbal medicine Chuanxiong, and is a well-known drug used for a variety of diseases. Studies have found that TMP inhibits inflammation, reduces oxidative stress, regulates cell apoptosis, prevents excitotoxicity, affects key apoptosis-related gene factors, promotes neuronal recovery, and inhibits the production of ROS in cells. TMP provides promising neuroprotective effects and can be used to develop effective neuroprotective drugs. Combining two pharmacophores to obtain new improved molecules is currently a means of exploring effective neuroprotective drugs (Bukhari, Syed Nasir Abbas and Ruchika Yogesh. "An Overview of Tetramethylpyrazine (Ligustrazine) and its Derivatives as Potent Anti-Alzheimer's Disease Agents." Letters in Drug Design & Discovery (2022): n.pag.). The present invention combines the main active ingredient TMP in the traditional Chinese medicine Chuanxiong with cinnamic acid compounds widely present in plants with spermidine and spermine, respectively, to give new compounds multiple mechanisms of action and multifunctional neuroprotective activity. Summary of the invention
[0006] Based on the important roles of spermidine and spermine in maintaining body homeostasis and normal physiological metabolism, on the one hand, the present invention aims to provide eight spermidine and spermine derivatives with neuroprotective activity.
[0007] The spermidine and spermine derivatives are stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs of spermidine and spermine compounds.
[0008] The present invention also provides eight pharmaceutical compositions comprising a pharmaceutically acceptable carrier and at least the spermidine, spermine derivative or its stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof.
[0009] A method for producing spermidine, a spermine derivative or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate or a prodrug thereof.
[0010] In another aspect, the present invention also provides the use of the spermidine and spermine derivatives in the preparation of drugs for treating diseases related to oxidative stress damage and free radicals, neurodegenerative diseases or glycolipid metabolic diseases.
[0011] First, the present invention provides spermidine and spermine derivatives.
[0012] Wherein, the compound is a compound as shown in Formula I or II, or a stereoisomer, a pharmaceutically acceptable salt, a solvate or a prodrug of the compound as shown in Formula I or II; wherein R 1 Preferably, cinnamic acid, acetylated p-coumaric acid, acetylated ferulic acid, ligustrazic acid, R 2 Preferred are cinnamic acid, acetylated p-coumaric acid, acetylated ferulic acid and ligustrazic acid.
[0013]
[0014] The pharmaceutically acceptable salt is sodium salt, potassium salt, calcium salt, hydrochloride, trifluoroacetate or zinc salt.
[0015] The specific structural formula of the compound is as follows:
[0016]
[0017]
[0018] The specific steps include:
[0019] (1) Dissolve p-coumaric acid / ferulic acid in 30 mL of acetic anhydride, add a catalytic amount of dimethylaminopyridine, and react at room temperature overnight. Monitor the reaction by TLC. After the reaction is complete, add 100 mL of water and stir for 2 h in an ice bath. A white solid precipitates. Place it in a refrigerator overnight, filter it, wash the filter cake with distilled water, and dry it in a vacuum drying oven to obtain a white solid. It can be directly carried out to the next step without purification;
[0020] (2) Dissolve TMP in 300 mL of water and add KMnO 4 , heated to 50°C, reacted for 10 hours. After the reaction was complete, cooled, extracted with ethyl acetate, the organic phase was discarded, the aqueous phase was adjusted to pH 3 with 10% hydrochloric acid, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain a yellow solid 3,5,6-trimethylpyrazine-2-carboxylic acid;
[0021] (3) Weigh cinnamic acid / acetylated p-coumaric acid / acetylated ferulic acid / ligustrazine acid and 2-mercaptothiazoline and dissolve them in 50 mL of dry dichloromethane solution, stir evenly, add N-methylimidazole, and then slowly add N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate in batches, and react at room temperature overnight. Monitor the reaction by TLC. After the reaction is completed, wash with water, then wash twice with dilute acid solution, wash with saturated brine, dry with anhydrous sodium sulfate, filter, concentrate, and purify by column chromatography (petroleum ether: ethyl acetate = 2:1) to obtain a yellow-green solid compound.
[0022] (4) Weigh an appropriate amount of spermidine / spermine and dissolve it in ultra-dry dichloromethane, stir evenly, slowly add the above 2-mercaptothiazolyl derivative dissolved in ultra-dry dichloromethane, react overnight, monitor the reaction by TLC, until the yellow-green color in the reaction solution turns colorless, and do not treat it. Add di-tert-butyl dicarbonate and triethylamine and react for 4 hours. After the reaction is completed, wash with dilute hydrochloric acid solution and saturated brine, dry with anhydrous sodium sulfate, and purify by column chromatography (dichloromethane: methanol = 50: 1) to obtain a white transparent oil. Dissolve the obtained white transparent oil in ultra-dry ethyl acetate, add 4M hydrogen chloride ethyl acetate solution under ice bath, react for 4 hours, and after monitoring the reaction completion by TLC, spin dry the solvent to obtain a white solid, add pure water to dissolve it, and then add NaHCO 3 The pH was adjusted to 8, the aqueous phase was extracted with dichloromethane, the organic phases were combined, and the solvent was spin-dried to obtain the target product.
[0023] The specific preparation process is as follows:
[0024]
[0025] (a)Ac 2 O,DMAP,rt,overniight,(b)KMnO 4 , H2 O, 50℃, overnight, (c) 2-Mercaptothiazoline, DCM, rt, overnight, (d) spermidine / spermine, DCM, rt, overnight, (e) Boc 2 O, Et 3 N,DCM,rt,4h,(f)HCl / EtOAc,0℃,4h.
[0026] Furthermore, the present invention also provides 8 compounds, which include the above-mentioned compounds shown in I and II, their stereoisomers, their pharmaceutically acceptable salts or solvates, and pharmaceutically acceptable adjuvants, carriers or diluents.
[0027] In some preferred embodiments, the dosage form of the composition is selected from plain tablets, film-coated tablets, sugar-coated tablets, enteric-coated tablets, dispersible tablets, capsules, granules, oral solutions or oral suspensions.
[0028] Again, the present invention also provides the spermidine / spermine stereoisomers, or pharmaceutically acceptable salts or solvates thereof for use in treating acid excitotoxicity, MEF2 dysfunction, diseases associated with oxidative stress damage and free radicals, neurodegenerative diseases or glycolipid metabolic diseases.
[0029] The diseases associated with oxidative stress damage or free radicals are: cerebral stroke, brain trauma, epilepsy, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Alzheimer's disease, hypoxia-ischemia, brain injury, cerebral hemorrhage, dementia, ischemic heart disease, vascular embolism, atherosclerosis, hypercholesterolemia, emphysema, cataract, diabetes, acute pancreatitis, alcohol-induced liver disease, kidney damage, or cancer;
[0030] The neurodegenerative disease is cerebral ischemia, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, ataxia-telangiectasia, bovine spongiform encephalopathy, Creutzfeldt-Jakob disease, Huntington's disease, cerebellar atrophy, multiple sclerosis, primary lateral sclerosis, or spinal muscular atrophy.
[0031] Among them, sugar and lipid metabolic diseases include hyperlipidemia, diabetes, fatty liver, obesity, hypertension or cardiovascular and cerebrovascular diseases.
[0032] If not otherwise specified, the compounds of the present invention are understood to include free states and salts thereof. The term "salt" means acidic and / or basic salts formed with inorganic and / or organic acids and bases. In addition, the term "salt includes zwitterions (inner salts), such as when the compound of formula I contains basic fragments such as amines or pyridine or imidazole rings, and acidic fragments such as carboxylic acids. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, such as acceptable metal and amine salts, in which the cation does not significantly contribute to the toxicity or biological activity of the salt. However, other salts may be useful, such as separation or purification steps used in the preparation process, and are therefore also included in the scope of the present invention. Salts of compounds of formula I are formed by compounds of formula I with a certain amount of acid or base, such as an equal amount, in a medium such as in which the salt can be precipitated or in its aqueous medium, and then lyophilized.
[0033] Exemplary acid addition salts include acetates (e.g., formed with acetic acid or a trihaloacetic acid such as trifluoroacetic acid), adipates, alginate, ascorbate, aspartate, benzoate, benzenesulfonate, bisulfate, borate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride (formed with hydrochloric acid), hydrobromide (formed with hydrobromic acid),
[0013] Examples of the invention include, but are not limited to, iodide, 2-hydroxyethanesulfonate, lactate, maleate (formed with maleic acid), methanesulfonate (formed with methanesulfonic acid), 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate (such as those formed with sulfuric acid), sulfonate (such as those mentioned herein), tartrate, thiocyanate, toluenesulfonate such as toluenesulfonate, undecanoate, and the like.
[0034] Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, potassium, calcium and zinc salts; alkaline earth metal salts such as calcium and magnesium salts; barium, zinc and aluminum salts; salts formed with organic bases (such as organic amines) such as trialkylamines such as triethylamine, procaine, dibenzylamine, N-benzyl-β-phenylethylamine, 1-diphenylhydroxymethylamine, N,N'-bisbenzylethylenediamine, dehydroabietylamine, N-ethylpiperidine, benzylamine, dicyclohexylamine or similar pharmaceutically acceptable amines and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups can be quaternized with agents such as lower alkyl halides (such as methyl, ethyl, propyl and butyl chlorides, bromides and iodides), dialkyl sulfates (such as dimethyl, diethyl, dibutyl and diamyl sulfates), long chain halides (such as decyl, dodecyl, tetradecyl and octadecyl chlorides, bromides and iodides), aralkyl halides (such as benzyl and phenethyl bromides) and others. Preferred salts include monohydrochloride, bisulfate, methanesulfonate, phosphate or nitrate salts.
[0035] The phrase "pharmaceutically acceptable" refers to those compounds, materials, compositions and / or dosage forms that are, within the scope of sound medical evaluation, suitable for use in contact with the tissues of humans and animals without undue toxicity, irritation, allergic response or other problems or complications, commensurate with a reasonable benefit / risk ratio.
[0036] As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds, wherein the parent compound is modified with an acid or its basic salt. Examples of pharmaceutically acceptable salts include, but are not limited to, inorganic or organic acid salts of basic groups such as amines; and alkali or organic salts of acidic groups such as carboxylic acids. Pharmaceutically acceptable salts include conventional non-toxic salts or quaternary ammonium salts of the parent compound, such as from non-toxic inorganic or organic acids. For example, these conventional non-toxic salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, aminosulfonic acid, phosphoric acid and nitric acid; and salts prepared from organic acids such as acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, pamoic acid, maleic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, sulfanilic acid, 2-ethoxybenzoic acid, fumaric acid, toluenesulfonic acid, methanesulfonic acid, ethanedisulfonic acid, oxalic acid and isethionic acid and their analogs.
[0037] The pharmaceutically acceptable salts of the present invention can be synthesized by conventional chemical methods from the parent compound containing the basic or acidic fragment. Typically, these salts can be prepared from the free acid or basic form of these compounds with a suitable base or acid in a stoichiometric ratio in water or an organic solvent, or a mixture thereof; typically, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile are preferred.
[0038] All stereoisomers of the compounds of the invention are contemplated, both in mixtures and in pure or substantially pure form. Stereoisomers include compounds of optical isomers through substitution of one or more chiral atoms, as well as compounds of optical isomers through restricted rotation of one or more bonds (atropisomers). The definition of the compounds of the invention includes all possible stereoisomers and mixtures thereof. It includes in particular racemic forms and isolated optical isomers with particular activity. The racemic forms are resolved by physical methods, such as distributed crystallization, separation or crystallization of stereoisomeric derivatives or separation by chiral column chromatography. The individual optical isomers are obtained by conventional methods from racemic salts, such as salts formed with optically active acids, and then crystallized.
[0039] Prodrugs and solvates of the compounds of the present invention are also contemplated. The term "prodrug" refers to a compound that, upon administration to a receptor, undergoes a chemical reaction metabolically or chemically to form a compound of formula I, II, and / or a salt and / or a solvate thereof. Any compound that is converted in vivo to provide a biologically active agent (i.e., a compound of formula I, II) is a prodrug within the scope and spirit of the present invention. For example, a compound containing a carboxyl group forms a physiologically hydrolyzable ester as a prodrug, which is hydrolyzed in vivo to form the compound of formula I, II itself. These prodrugs are preferably administered orally, since hydrolysis under many conditions occurs substantially under the influence of digestive enzymes. With parenteral administration, the ester itself is active, and in those instances, hydrolysis occurs in the blood. Examples of physiologically hydrolyzable esters of compounds of formula I, II include C 1-6 Alkylbenzyl, 4-methoxybenzyl, indanyl, phthaloyl, methoxymethyl, C 1-6 Alkanoyloxy-C 1-6 Alkyl groups such as acetoxymethyl, pivaloyloxymethyl or propoxymethyl, C 1-6 Alkoxycarbonyloxy-C 1-6 Alkyl, such as methoxycarbonyl-oxymethyl or ethoxycarbonyloxymethyl, glycyloxymethyl, phenylglycyloxymethyl, (5-methyl-2-oxo-1,3-dioxol-4-yl)-methyl and other well-known physiologically hydrolyzed esters used, for example in the field of penicillin and cephalogensporin. These esters are prepared by conventional techniques known in the prior art. Various forms of prodrugs are well known in the prior art.
[0040] "Pharmaceutically acceptable carrier" generally refers to a carrier that is generally accepted in the art for delivering biologically active agents to animals, especially mammals. The formulation of a pharmaceutically acceptable carrier is based on many factors well known to those of ordinary skill in the art. These include, without limitation, the type and identity of the active agent being formulated; the recipient to which the agent-containing composition is administered; the route of administration of the composition; and the targeted therapeutic indication. Pharmaceutically acceptable carriers include aqueous and non-aqueous liquid media, as well as a variety of solid and semisolid dosage forms. These carriers include many different components and additives, and in addition to the active agent, these additional components are included in the formulation for a variety of reasons, such as stability of the active agent with the binder, which is well known to those of ordinary skill in the art.
[0041] The compounds of formula I and II of the present invention can be administered in any suitable manner to treat symptoms, depending on the site-specific treatment or the amount of drug delivered. Topical administration is generally preferred for systemic treatment of skin-related diseases, cancerous or precancerous symptoms, but other modes of delivery are also considered. For example, the compound is administered orally, such as in the form of tablets, capsules, granules, powders or liquid formulations including syrups; topically, such as in the form of solutions, suspensions, gels or ointments; sublingually; buccally; parenterally, such as by subcutaneous, intravenous, intramuscular or intrasternal injection or perfusion (such as sterile water or non-aqueous solutions or suspensions); nasally, such as by inhalation spray; topically, such as in the form of emulsions or ointments; rectally, such as in the form of suppositories; or liposomes. A dosage unit formulation containing a non-toxic, pharmaceutically acceptable excipient or diluent can be administered. The compound can be administered in a form that can release immediately or in a delayed release form. Suitable pharmaceutical compositions for immediate release or delayed release are obtained, and in the example of partial delayed release, devices such as subcutaneous implants or osmotic pumps are used.
[0042] Exemplary compositions for oral administration include suspensions, which may contain, for example, microcrystalline cellulose for delivery, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners or flavorings known in the art; immediate release tablets may contain, for example, microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and / or lactose and / or other excipients, binders, expanders, disintegrants, diluents and lubricants such as those known in the art. The compounds of the present invention can also be delivered orally by sublingual and / or buccal administration, such as compression molded, compressed or lyophilized tablets. Exemplary compositions include rapidly dissolving diluents such as mannitol, lactose, sucrose and / or cyclodextrins. Included in these formulations can also be high molecular weight excipients such as cellulose. or polyethylene glycol (PEG); excipients that aid mucosal adhesion such as hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), sodium carboxymethyl cellulose (SCMC) and / or maleic anhydride copolymers (such as ); and controlled release agents such as polyacrylic acid copolymers (such as ). Lubricants, glidants, flavors, colorants and stabilizers can also be added to facilitate preparation and use.
[0043] Exemplary compositions for administration by nebulization or inhalation include solutions containing benzyl alcohol or other suitable preservatives, absorption enhancers to enhance absorbability and / or bioactivity, and / or other solubilizing or dispersing agents such as those known in the art.
[0044] Exemplary compositions for parenteral administration include injectable solutions or suspensions, which may contain, for example, suitable non-toxic, parenterally acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution, isotonic sodium chloride solution, or other suitable dispersing or wetting and suspending agents, including synthetic mono- or diglycerides, and fatty acids including oleic acid.
[0045] Exemplary compositions for rectal administration include suppositories, which may contain, for example, suitable non-irritating excipients such as cocoa butter, synthetic glycerides or polyethylene glycols which are solid at ordinary temperatures but dissolve and / or melt in the stomach to release the drug. BRIEF DESCRIPTION OF THE DRAWINGS
[0046] Figure 1 DPPH scavenging ability diagram of the present invention;
[0047] Figure 2 This is a graph comparing the hydroxyl radical (·OH) scavenging ability of the Fenton method of the present invention;
[0048] Figure 3 The superoxide anion (O 2 ·- ) Clear capability map;
[0049] Figure 4 This is a graph showing the neuroprotective activity of the compounds of the present invention on HT22 and N2a cells stimulated by glutamate;
[0050] Figure 5 This is a graph showing the anti-neuroinflammatory activity of the compounds of the present invention on LPS-induced BV2 cells; DETAILED DESCRIPTION
[0051] The technical solutions in the embodiments of the present invention will be described clearly and completely below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention. All raw materials and solvents used in the embodiments are purchased from Sigma Biochemical and Organic Compounds for Research and Diagnostic Clinical Reagents.
[0052] Example 1: Preparation method of spermidine derivatives
[0053] N-(3-((4-cinnamamidebutyl)amino)propyl)cinnamamide (Spd-1) comprises the following steps:
[0054] (1) Weigh cinnamic acid (3 g, 20.25 mM) and 2-mercaptothiazoline (2.29 g, 19.24 mM) and dissolve them in 50 ml of dry dichloromethane solution, stir evenly, add N-methylimidazole (3.39 mL, 42.53 mM), then slowly add N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (5.68 g, 20.25 mM) in batches, and react at room temperature overnight. Monitor the reaction by TLC. After the reaction is completed, wash with water, then wash twice with dilute acid solution, wash with saturated brine, dry over anhydrous sodium sulfate, filter, concentrate, and purify by column chromatography (petroleum ether: ethyl acetate = 2:1) to obtain a yellow-green solid compound.
[0055] (2) Spermidine (78.64 μL, 541.42 μM) was dissolved in ultra-dry dichloromethane, stirred evenly at room temperature, and the ultra-dry dichloromethane solution containing (270 mg, 1.08 mM) of the compound was slowly added dropwise. After the addition was completed, the reaction was allowed to proceed overnight at room temperature. The reaction was monitored by TLC until the green color in the system disappeared and turned colorless and transparent. The reaction was completed. Without extraction, di-tert-butyl dicarbonate (119.25 μL, 540.02 μM) and triethylamine were directly added. (75.02 μL, 540.02 μM) was reacted for 4 h. After the reaction was completed, it was washed with dilute hydrochloric acid solution and saturated brine, dried over anhydrous sodium sulfate, and purified by column chromatography (dichloromethane: methanol = 50: 1) to obtain a white transparent oil. The obtained white transparent oil was dissolved in ultra-dry ethyl acetate, and 4M hydrogen chloride ethyl acetate solution was added under ice bath. After reacting for 4 h, after TLC monitoring, the solvent was dried, pure water was added to dissolve, and NaHCO 3 The pH was adjusted to 8, the aqueous phase was extracted with dichloromethane, the organic phases were combined, and the solvent was dried to obtain the target product: 4-((E)-3-((3-((4-((E)-3-(4-acetoxyphenyl)acrylamide)butyl)amino)propyl)amino)-3-oxopropen-1-yl)phenyl acetate.
[0056] (3) The synthesis steps of the Spd-1 are:
[0057]
[0058] (a) 2-Mercaptothiazoline, DCM, rt, overnight, (b) spermidine, DCM, rt, overnight, (c) Boc 2 O,Et 3 N,DCM,rt,4h,(f)HCI / EtOAc,0℃,4h.
[0059] The nuclear magnetic hydrogen spectrum data of the Spd-1 compound are:
[0060] ESI-MS: [M+H] + m / z 522.25. 1 H NMR (400MHz, DMSO-d6) δ8.32(t,J=5.9Hz,1H),8.16(d,J=5.9Hz,1H),7.40-7.29(m,6H),6.80(d,J=8.2Hz,4H),6.46(d,J=2.5Hz,1H),6.42(d,J= 2.5Hz, 1H), 3.20 (dt, J = 24.1, 6.1Hz, 4H), 2.88 (q, J = 6.9Hz, 4H), 1.82 (p, J = 6.9Hz, 2H), 1.65 (dq, J = 15.5, 7.9, 7.2Hz, 2H), 1.51 (q, J = 7.2Hz, 2H).
[0061] 4-((E)-3-((3-((4-((E)-3-(4-acetoxyphenyl)acrylamide)butyl)amino)propyl)amino)-3-oxopropen-1-yl)phenyl acetate (Spd-2) comprises the following steps:
[0062] (1) Dissolve p-coumaric acid (2 g, 11.1 mM) in 30 mL of acetic anhydride, add a catalytic amount of dimethylaminopyridine, and react at room temperature overnight. Monitor the reaction by TLC. After the reaction is complete, add 100 mL of water and stir for 2 h in an ice bath. A white solid precipitates. Place it in a refrigerator overnight, filter it, wash the filter cake with distilled water, and dry it in a vacuum drying oven to obtain a white solid. Proceed directly to the next step without purification;
[0063] (2) Weigh the white solid (1 g, 6.09 mm) and 2-mercaptothiazoline (689.81 mg, 5.79 mM) and dissolve them in 50 mL of dry dichloromethane solution, stir evenly, add N-methylimidazole (1.02 mL, 12.79 mM), and then slowly add N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (1.44 g, 5.12 mM) in batches, and react at room temperature overnight. Monitor the reaction by TLC. After the reaction is completed, wash with water, then wash twice with dilute acid solution, wash with saturated brine, dry over anhydrous sodium sulfate, filter, concentrate, and purify by column chromatography (petroleum ether: ethyl acetate = 2:1) to obtain a yellow-green solid compound.
[0064] (3) Spermidine (79.62 μL, 548.18 μM) was dissolved in ultra-dry dichloromethane, stirred evenly at room temperature, and the ultra-dry dichloromethane solution containing 337 mg of yellow-green solid compound was slowly added dropwise. After the addition was completed, the reaction was allowed to react overnight at room temperature. The reaction was monitored by TLC until the green color in the system disappeared and turned colorless and transparent. The reaction was completed. Without extraction, di-tert-butyl dicarbonate (119.25 μL, 546.38 μM) and triethylamine (75.02 μL, 546.38 μM) were directly added to react for 4 h. After the reaction was completed, the mixture was washed with dilute hydrochloric acid solution and saturated brine, dried over anhydrous sodium sulfate, and purified by column chromatography (dichloromethane: methanol = 50:1) to obtain a white transparent oil. The obtained white transparent oil was dissolved in ultra-dry ethyl acetate, and 4 M hydrogen chloride ethyl acetate solution was added under ice bath. After the reaction was completed for 4 h, the solvent was dried by spin drying, dissolved in pure water, and then NaHCO 3 The pH was adjusted to 8, the aqueous phase was extracted with dichloromethane, the organic phases were combined, and the solvent was dried to obtain the target product: 4-((E)-3-((3-((4-((E)-3-(4-acetoxyphenyl)acrylamide)butyl)amino)propyl)amino)-3-oxopropen-1-yl)phenyl acetate.
[0065] (4) The synthesis steps of the Spd-2 are:
[0066]
[0067] (a)Ac 2 O,DMAP,rt,overnight,(b)2-Mercaptothiazoline,DCM,rt,,overnight,(c)spermidine,,DCM,rt,overnight,(d)Boc 2 O, Et 3 N, DCM, rt, 4h, (e) HCI / EtOAc, 0℃, 4h.
[0068] The nuclear magnetic hydrogen spectrum data of the Spd-2 compound are:
[0069] ESI-MS: [M+H] + m / z 522.25. 1 H NMR (400 MHz, DMSO-d 6)δ8.32(t,J=5.9Hz,1H),8.16(d,J=5.9Hz,1H),7.40–7.29(m,6H),6.80(d,J=8.2Hz,4H),6.46(d,J=2.5Hz,1H),6.42(d,J=2.5Hz,1H) ,3.20(dt,J=24.1,6.1Hz,4H),2.88(q,J=6.9Hz,4H),1.82(p,J=6.9Hz,2H),1.65(dq,J=15.5,7.9,7.2Hz,2H),1.51(q,J=7.2Hz,2H).
[0070] 4-((E)-3-((3-((4-((E)-3-(4-acetoxy-3-methoxyphenyl)acrylamide)butyl)amino)propyl)amino)-3-oxopropen-1-yl)-2-methoxyphenyl acetate (Spd-3) comprises the following steps:
[0071] (1) Dissolve ferulic acid (2 g, 11.22 mM) in 30 mL of acetic anhydride, add a catalytic amount of dimethylaminopyridine, and react at room temperature overnight. Monitor the reaction by TLC. After the reaction is complete, add 100 mL of water and stir for 2 h in an ice bath. A white solid precipitates. Place in a refrigerator overnight, filter, wash the filter cake with distilled water, and dry in a vacuum drying oven to obtain a light green solid. Proceed directly to the next step without purification.
[0072] (2) Weigh the light green solid (700 mg, 2.96 mM) and 2-mercaptothiazoline (689.81 mg, 5.79 mM) and dissolve them in 50 mL of dry dichloromethane solution, stir evenly, add N-methylimidazole (0.496 mL, 8.95 mM), and then slowly add N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (997.73 mg, 3.56 mM) in batches, and react at room temperature overnight. Monitor the reaction by TLC. After the reaction is completed, add water to wash, then wash twice with dilute acid solution, wash with saturated brine, dry over anhydrous sodium sulfate, filter, concentrate, and purify by column chromatography (petroleum ether: ethyl acetate = 2:1) to obtain a yellow-green solid compound 3.
[0073] (3) Spermidine (53.60 μL, 368.99 μM) was dissolved in ultra-dry dichloromethane, stirred evenly at room temperature, and the ultra-dry dichloromethane solution containing 270 mg of yellow-green solid compound 2 was slowly added dropwise. After the addition was completed, the reaction was allowed to proceed overnight at room temperature. The reaction was monitored by TLC until the green color in the system disappeared and turned colorless and transparent. The reaction was completed. Without extraction, (80.30 μL, 367.91 μM) of di-tert-butyl dicarbonate and (50.52 μL, 367.91 μM) of triethylamine were directly added to react for 4 h. After the reaction was completed, the mixture was washed with dilute hydrochloric acid solution and saturated brine, dried over anhydrous sodium sulfate, and purified by column chromatography (dichloromethane: methanol = 50:1) to obtain a white transparent oil. The obtained white transparent oil was dissolved in ultra-dry ethyl acetate, and 4 M hydrogen chloride ethyl acetate solution was added under ice bath. After the reaction was completed for 4 h, the solvent was dried by spin drying, dissolved in pure water, and then NaHCO 3 The pH was adjusted to 8, the aqueous phase was extracted with dichloromethane, the organic phases were combined, and the solvent was dried to obtain the target product: 4-((E)-3-((3-((4-((E)-3-(4-acetoxy-3-methoxyphenyl)acrylamide)butyl)amino)propyl)amino)-3-oxopropene-1-yl)-2-methoxyphenyl acetate.
[0074] (4) The synthesis steps of the Spd-3 are:
[0075]
[0076] (a)Ac 2 O,DMAP,rt,overnight,(b)2-Mercaptothiazoline,DCM,rt,overnight,(c)spermidine,DCM,rt,,overnight,(d)Boc 2 O, Et 3 N, DCM, rt, 4h, (e) HCI / EtOAc, 0℃, 4h.
[0077] The nuclear magnetic hydrogen spectrum data of the Spd-3 compound are:
[0078] ESI-MS: [M+H] + m / z 582.27. 1H NMR (400MHz, DMSO-d6) δ8.41 (s, 1H), 8.26 (d, J = 5.7Hz, 1H), 7.42 (dd, J = 15.6, 8.5Hz, 2H), 7.32 (d, J = 4.6Hz, 2H), 7.20-7.06 (m, 5H) ,6.73-6.61(m,2H),3.80(s,6H),3.23(dd,J=24.8,6.0Hz,4H),2.90(s,4H),2.25(s,6H),1.84(t,J=7.3Hz,2H),1.72-1.47(m,5H).
[0079] 3,5,6-trimethyl-N-(3-((4-(3,5,6-trimethylpyrazine-2-carboxamide)butyl)amino)propyl)pyrazine-2-carboxamide (Spd-4) comprises the following steps:
[0080] (1) Dissolve TMP (13.6 g, 100.0 mM) in 300 mL of water and add KMnO in batches. 4 (31.6g, 200.0mM), heated to 50℃, reacted for 10h. After the reaction was complete, cooled, extracted with ethyl acetate, discarded the organic phase, adjusted the pH value of the aqueous phase to 3 with 10% hydrochloric acid, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and evaporated the solvent under reduced pressure to obtain a yellow solid 1;
[0081] (2) Chuanxiongpiric acid (850 mg, 5.11 mM) and 2-mercaptothiazoline (426.79 mg, 3.58 mM) were dissolved in 50 mL of dry dichloromethane solution, stirred evenly, and N-methylimidazole (0.723 mL, 9.07 mM) was added, and then N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (1.21 g, 4.32 mM) was slowly added in batches, and reacted at room temperature overnight. TLC was used to monitor the reaction. After the reaction was completed, water was added for washing, and then washed twice with a dilute acid solution, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (petroleum ether: ethyl acetate = 2:1) to obtain a yellow-green solid compound 4.
[0082] (3) Spermidine (135.82 μL, 935.05 μM) was dissolved in ultra-dry dichloromethane, stirred evenly at room temperature, and the ultra-dry dichloromethane solution containing 500 mg of yellow-green solid compound 4 was slowly added dropwise. After the addition was completed, the reaction was allowed to proceed overnight at room temperature. The reaction was monitored by TLC until the green color in the system disappeared and turned colorless and transparent. The reaction was completed. Without extraction, (197.7 μL, 905.84 μM) of di-tert-butyl dicarbonate and (124.38 μL, 905.84 μM) of triethylamine were directly added to react for 4 h. After the reaction was completed, the mixture was washed with dilute hydrochloric acid solution and saturated brine, dried over anhydrous sodium sulfate, and purified by column chromatography (dichloromethane: methanol = 50:1) to obtain a white transparent oil. The obtained white transparent oil was dissolved in ultra-dry ethyl acetate, and 4 M hydrogen chloride ethyl acetate solution was added under ice bath. After the reaction was completed for 4 h, the solvent was dried by spin drying, dissolved in pure water, and then NaHCO 3 The pH was adjusted to 8, the aqueous phase was extracted with dichloromethane, the organic phases were combined, and the solvent was dried by spin drying to obtain the target product: 3,5,6-trimethyl-N-(3-((4-(3,5,6-trimethylpyrazine-2-carboxamide)butyl)amino)propyl)pyrazine-2-carboxamide.
[0083] (4) The synthesis steps of the Spd-4 are:
[0084]
[0085] (a) KMnO 4 , H 2 O, 50℃, overnight, (b) 2-Mercaptothiazoline, DCM, rt, overnight, (c) spermidine, DCM, rt, overnight, (d) Boc 2 O, Et 3 N, DCM, rt, 4h, (e) HCl / EtOAc, 0℃, 4h.
[0086] The nuclear magnetic hydrogen spectrum data of the Spd-4 compound are:
[0087] ESI-MS: [M+H] + m / z 442.29. 1H NMR(500MHz,Chloroform-d)δ8.37(t,J=6.2Hz,1H),8.14-8.07(m,1H),3.54(q,J=6.4Hz,2H),3.45(q,J=6.6Hz,2H), 2.89(d,J=7.7Hz,6H), 2.77(dt,J=20.5,6.6Hz,6H), 2.55(d,J=3.2Hz,6H), 1.86(p,J=6.7Hz,2H), 1.73-1.65(m,4H).
[0088] 4-((E)-3-((3-((4-((E)-3-(3,4-diacetoxyphenyl)acrylamide)butyl)amino)propyl)amino)-3-oxopropen-1-yl)-1,2-phenylene diacetate (Spd-5) comprises the following steps:
[0089] (1) Add acetic anhydride (42 mL, 456.87 mM) to caffeic acid (5 g, 30.46 mM) and add 4-dimethylaminopyridine (372.11 mg, 3.05 mM) to fully dissolve the caffeic acid. Then, react overnight at room temperature. After the reaction, add pure water to the reaction flask and continue stirring for 4 h under ice bath. At this time, solid gradually precipitates and is immediately filtered. The filter cake is washed with pure water and collected. After vacuum drying for 24 h, (E)-3-(4-acetoxyphenyl)acrylic acid is obtained as a light brown powdery solid.
[0090] (2) Weigh (E)-3-(4-acetoxyphenyl)acrylic acid (700 mg, 4.26 mM) and 2-mercaptothiazoline (482 mg, 4.05 mM) and dissolve in 20 mL of dry dichloromethane solution, stir evenly, add N-methylimidazole (0.713 mL, 8.95 mM), slowly add N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (1.44 g, 5.12 mM) in batches, and react at room temperature overnight. TLC monitors the reaction. After the reaction is completed, add water to wash, then wash twice with 1M HCl solution, wash with saturated brine, dry over anhydrous sodium sulfate, filter, concentrate, and purify by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain a yellow-green solid compound.
[0091] (3) Spermidine (78 μL, 541.42 μM) was dissolved in ultra-dry dichloromethane, stirred evenly at room temperature, and the ultra-dry dichloromethane solution containing a yellow-green solid compound (270 mg, 1.08 mM) was slowly added dropwise. After the addition was completed, the reaction was allowed to proceed overnight at room temperature. The reaction was monitored by TLC until the green color in the system disappeared and turned colorless and transparent. The reaction was completed. Without extraction, di-tert-butyl dicarbonate (117.86 μL, 540.02 μM) and triethylamine (74.15 μL, 540.02 μM) were directly added and reacted for 4 h. After the reaction was completed, the product was washed with dilute hydrochloric acid solution and saturated brine, dried over anhydrous sodium sulfate, and purified by column chromatography (dichloromethane: methanol = 50:1) to obtain a white transparent product. The obtained white transparent oil was dissolved in ultra-dry ethyl acetate, and 4M hydrogen chloride ethyl acetate solution was added under ice bath. After reacting for 4 hours, after the reaction was completed as monitored by TLC, the solvent was dried to obtain 4-((E)-3-((3-((4-((E)-3-(3,4-dia-cetoxyphenyl)acrylamido)butyl)amino)propyl)amino)-3-oxoprop-1-yl)-1,2-phenylenediacetate hydrochloride (Spd-5).
[0092] (4) The synthesis steps of the Spd-5 are:
[0093]
[0094] (a)Ac 2 O,DMAP,rt,overnight,(b)2-Mercaptothiazoline,DCM,rt,overnight,(c)spermidine,DCM,rt,overnight,(d)Boc 2 O, Et 3 N, DCM, rt, 4h, (e) HCl / EtOAc, 0℃, 4h.
[0095] The nuclear magnetic hydrogen spectrum data of the Spd-5 compound are:
[0096] ESI-MS: [M+H] + m / z 638.22. 1H NMR (500MHz, DMSO-d6) δ8.87 (s, 2H), 8.48 (t, J = 5.7Hz, 1H), 8.34 (t, J = 5.6Hz, 1H), 7.50 (dd ,J=13.7,7.9Hz,4H),7.42(dd,J=15.7,10.1Hz,2H),7.32(s,1H),7.30(s,1H),6.67(d,J=3. 0Hz, 1H), 6.64 (d, J=3.0Hz, 1H), 3.23 (dd, J=30.2, 6.1Hz, 5H), 2.95-2.87 (m, 4H), 2.29 (d, J= 3.9Hz, 12H), 1.84 (q, J = 10.2, 6.7Hz, 2H), 1.65 ( q, J = 7.2, 6.4Hz, 2H), 1.52 ( t, J = 7.3Hz, 2H).
[0097] (E)-3-(4-hydroxyphenyl)-N-(3-((4-((E)-3-(4-hydroxyphenyl)acrylamido)butyl)amino)propyl)acrylamide (Spd-6)
[0098] (1) The steps are similar to those of Spd-2, except that the white transparent oil is purified by column chromatography (dichloromethane: methanol = 50: 1). The white transparent oil is dissolved in methanol, stirred evenly, heated to 50°C, and a 4M sodium methoxide methanol solution is slowly added to react overnight. After the reaction is completed, the pH is adjusted to 5 with a 1M hydrochloric acid methanol solution, the solvent is dried, and purified by column chromatography (dichloromethane: methanol = 10: 1) to obtain a white transparent oil. The obtained white transparent oil was dissolved in ultra-dry ethyl acetate, and 4 M hydrogen chloride ethyl acetate solution was added under ice bath. After reacting for 4 hours, after the reaction was completed as monitored by TLC, the solvent was dried to obtain (E)-3-(4-hydroxyphenyl)-N-(3-((4-((E)-3-(4-hydroxyphenyl)acrylamido)butyl)amino)propyl)acrylamide hydrochloride ((E)-3-(4-hydroxyphenyl)-N-(3-((4-((E)-3-(4-hydroxyphenyl)acrylamido)butyl)amino)propyl)acrylamide, Spd-6).
[0099] (2) The Spd-6 synthesis steps are:
[0100]
[0101] (a) DCM, rt, 12h, (b) Boc 2 O, Et 3N,DCM,rt,4h,(c)MeONa / MeOH,rt,overnight,(d)HCl / EtOAc,0℃,4h.
[0102] The nuclear magnetic hydrogen spectrum data of the Spd-6 compound are:
[0103] ESI-MS: [M+H] + m / z 438.20. 1 H NMR (500MHz, DMSO-d6) δ8.91 (s, 2H), 8.36 (d, J = 5.7Hz, 1H), 8.20 (t, J = 5.0Hz, 1H), 7.38 (dd,J=8.5,5.0Hz,4H),7.33(dd,J=15.7,10.5Hz,2H),6.82(s,2H),6.80(s,2H),6.46( d,J=3.1Hz,1H),6.43(d,J=3.1Hz,1H),3.24(q,J=6.3Hz,2H),3.18(q,J=6.3Hz,2H),2. 88 (d, J = 9.1 Hz, 4H), 1.83 (p, J = 6.7 Hz, 2H), 1.64 (q, J = 8.1 Hz, 2H), 1.50 (t, J = 7.4 Hz, 2H).
[0104] (E)-3-(4-hydroxy-3-methoxyphenyl)-N-(3-((4-((E)-3-(4-hydroxy-3-methoxyphenyl)acrylamide)butyl)amino)propyl)acrylamide (Spd-7)
[0105] (1) The steps are similar to those of Spd-3, except that the product is purified by column chromatography (dichloromethane: methanol = 50: 1) to obtain a white transparent oil. The white transparent oil is dissolved in methanol, stirred evenly, heated to 50°C, and a 4M sodium methoxide methanol solution is slowly added to react overnight. After the reaction is completed, the pH is adjusted to 5 with a 1M hydrochloric acid methanol solution, the solvent is dried, and purified by column chromatography (dichloromethane: methanol = 10: 1) to obtain a white transparent oil. The obtained white transparent oil was dissolved in ultra-dry ethyl acetate, and 4 M hydrogen chloride ethyl acetate solution was added under ice bath. After reacting for 4 h, the reaction was completed after TLC monitoring, and the solvent was dried to obtain (E)-3-(4-hydroxy-3-methoxyphenyl)-N-(3-((4-((E)-3-(4-hydroxy-3-methoxyphenyl)acrylamido)butyl)amino)propyl)acrylamide hydrochloride ((E)-3-(4-hydroxy-3-methoxyphenyl)-N-(3-((4-((E)-3-(4-hydroxy-3-methoxyphenyl)acrylamido)butyl)amino)propyl)acrylamide, Spd-7).
[0106] (2) The Spd-7 synthesis steps are:
[0107]
[0108] (a)Ac 2 O,DMAP,rt,overnight,(b)2-Mercaptothiazoline,DCM,rt,overnight,(c)spermidine,DCM,rt,overnight,(d)Boc 2 O,Et3N,DCM,rt,4h(e)HCl / EtOAc,0℃,4h.
[0109] The nuclear magnetic hydrogen spectrum data of the Spd-7 compound are:
[0110] ESI-MS: [M+H] + m / z 498.25. 1H NMR(500MHz,DMSO-d6)δ8.98(s,2H),8.33(t,J=5.8Hz,1H),8.18(t,J=5.7Hz,1H),7.33(dd,J=15 .7,11.0Hz,2H),7.12(dd,J=5.3,1.9Hz,2H),7.01-6.96(m,2H),6.82(dd,J=8.1,1.4Hz,2H),6.5 1(d,J=3.7Hz,1H),6.47(d,J=3.7Hz,1H),3.79(s,6H),3.25(q,J=6.0Hz,2H),3.18(q,J=6.2Hz,2 H), 2.92-2.85 (m, 4H), 1.83 (q, J = 7.2Hz, 2H), 1.67 (dd, J = 14.1, 8.5Hz, 2H), 1.51 (q, J = 7.2Hz, 2H).
[0111] Example 2: Preparation method of spermine derivatives
[0112] (2E,2'E)-N,N'-((butane-1,4-diylbis(azodiyl))bis(propane-3,1-diyl))bis(3-phenylacrylamide)(Spm-1)
[0113] (1) Synthesis steps refer to Spd-1
[0114] (2) The synthesis steps of Spm-1 are:
[0115]
[0116] (a)2-Mercaptothiazoline,DCM,rt,overnight, (b)spermine,DCM,rt,overnight,(c)Boc 2 O,Et 3 N,DCM,rt,4h,(f)HCI / EtOAc,0℃,4h.
[0117] The nuclear magnetic hydrogen spectrum data of the Spm-1 compound are:
[0118] ESI-MS: [M+H] + m / z 463.30. 1H NMR(500MHz,DMSO-d6)δ8.44(d,J=6.3Hz,2H),7.56(d,J=7.1Hz,4H),7.40(dt,J=12.8,5.0Hz,8H), 6.67 (s, 1H), 6.64 (s, 1H), 3.26 (d, J = 6.0Hz, 5H), 2.90 (d, J = 11.1Hz, 9H), 1.85 (s, 5H), 1.70 (s, 4H).
[0119] ((1E,19E)-3,18-dioxo-4,8,13,17-tetraaza-1,19-diene-1,20-diyl)bis(4,1-phenylene) diacetate (Spm-2)
[0120] (1) Synthesis steps refer to Spd-2
[0121] (2) The synthesis steps of Spm-2 are:
[0122]
[0123] (a)Ac 2 O,DMAP,rt,overnight,(b)2-Mercaptothiazoline,DCM,rt,overnight,(c)spermine,DCM,rt,overnight,(d)Boc 2 O, Et 3 N, DCM, rt, 4h, (e) HCl / EtOAc, 0℃, 4h.
[0124] The nuclear magnetic hydrogen spectrum data of the Spm-2 compound are:
[0125] ESI-MS: [M+H] + m / z 579.31. 1 H NMR (400MHz, DMSO-d6) δ8.42(t,J=5.8Hz,2H),7.67-7.55(m,4H),7.44(d,J=15.7Hz,2H),7.21-7.11(m,4H),6.64(s,1H ), 6.60 (s, 1H), 3.26 (q, J = 6.5Hz, 4H), 2.94 (t, J = 7.5Hz, 8H), 2.28 (s, 6H), 1.80 (q, J = 7.3, 6.9Hz, 4H), 1.69-1.60 (m, 4H).
[0126] ((1E,19E)-3,18-dioxo-4,8,13,17-tetraaza-1,19-diene-1,20-diyl)bis(2-methoxy-4,1-phenylene) diacetate (Spm-3)
[0127] (1) Synthesis steps refer to Spd-3
[0128] The synthesis steps of the Spm-3 are:
[0129]
[0130] (a)Ac 2 O,DMAP,rt,overnight(b)2-Mercaptothiazoline,DCM,rt,overnight,(c)spermine,DCM,rt,overnight,(d)BoC 2 O, Et 3 N, DCM, rt, 4h, (e) HCl / EtOAC, 0℃, 4h.
[0131] The nuclear magnetic hydrogen spectrum data of the Spm-3 compound are:
[0132] ESI-MS: [M+H] + m / z 638.26. 1 H NMR (400MHz, DMSO-d6) δ8.39(t,J=5.8Hz,2H),7.44(d,J=15.7Hz,2H),7.33(d,J=1.9Hz,2H),7.20-7.08(m,4H),6 .66(d,J=15.8Hz,2H),3.81(s,7H),3.27(q,J=6.4Hz,4H),2.26(s,7H), 1.81(p,J=6.9Hz,5H),1.70-1.61(m,4H).
[0133] N,N'-((Butane-1,4-diylbis(azadiyl))bis(propane-3,1-diyl))bis(3,5,6-trimethylpyrazine-2-carboxamide)(Spm-4)
[0134] (1) Synthesis steps refer to Spd-4
[0135] (2) The synthesis steps of Spm-4 are:
[0136]
[0137] (a) KMnO 4 , H 2O,50℃,overnight,(b)2-Mercaptothiazoline,DCM,rt,overnight,(c)spermidine,DCM,rt,overnight,(d)Boc 2 O, Et 3 N, DCM, rt, 4h, (e) HCl / EtOAc, 0℃, 4h.
[0138] The nuclear magnetic hydrogen spectrum data of the Spm-4 compound are:
[0139] ESI-MS: [M+H] + m / z 499.34. 1 H NMR (500MHz, DMSO-d6) δ8.85 (s, 2H), 2.86 (s, 9H), 2.67 (s, 8H), 1.90-1.87 (m, 4H), 1.70 (s, 4H).
[0140] (2E,2'E)-N,N'-((butane-1,4-diylbis(azodiyl))bis(propane-3,1-diyl))bis(3-(4-hydroxyphenyl)acrylamide)(Spm-5)
[0141] (1) Synthesis steps refer to Spd-6
[0142] (2) The synthesis steps of Spm-5 are:
[0143]
[0144] (a)Ac 2 O,DMAP,rt,overnight(b)2-MercaptothiazolineDCM,rt,overnight,(c)spermineDCM,rt,overnight(d)Boc 2 O,Et 3 N, DCM, rt, 4h, (e) MeONa / MeOH, 50℃, overnight, (f) HCI / EtOAc, 0℃, 4h.
[0145] The nuclear magnetic hydrogen spectrum data of the Spm-5 compound are:
[0146] ESI-MS: [M+H] + m / z 438.20. 1H NMR (500MHz, DMSO-d6) δ8.91 (s, 2H), 8.36 (d, J = 5.7Hz, 1H), 8.20 (t, J = 5.0Hz, 1H), 7.38 (dd,J=8.5,5.0Hz,4H),7.33(dd,J=15.7,10.5Hz,2H),6.82(s,2H),6.80(s,2H),6.46( d,J=3.1Hz,1H),6.43(d,J=3.1Hz,1H),3.24(q,J=6.3Hz,2H),3.18(q,J=6.3Hz,2H),2. 88 (d, J = 9.1 Hz, 4H), 1.83 (p, J = 6.7 Hz, 2H), 1.64 (q, J = 8.1 Hz, 2H), 1.50 (t, J = 7.4 Hz, 2H).
[0147] (E)-3-(4-hydroxy-3-methoxyphenyl)-N-(3-((4-((E)-3-(4-hydroxy-3-methoxyphenyl)acrylamide)butyl)amino)propyl)acrylamide (Spm-6)
[0148] (1) Synthesis steps refer to Spd-7
[0149] (2) Synthesis steps of Spm-6:
[0150]
[0151] (a)Ac 2 O,DMAP,rt,overnight,(b)2-Mercaptothiazoline,DCM,rt,overnight,(c)spermine,DCM,rt,overnight(d)Boc 2 O,Et 3 N, DCM, rt, 4h, (e) MeONa / MeOH, 50℃, overnight, (f) HCl / EtOAc, 0℃, 4h.
[0152] The nuclear magnetic hydrogen spectrum data of the Spm-6 compound are:
[0153] ESI-MS: [M+H] + m / z 498.25. 1H NMR(500MHz,DMSO-d6)δ8.98(s,2H),8.33(t,J=5.8Hz,1H),8.18(t,J=5.7Hz,1H),7.33(dd,J=15 .7,11.0Hz,2H),7.12(dd,J=5.3,1.9Hz,2H),7.01-6.96(m,2H),6.82(dd,J=8.1,1.4Hz,2H),6.5 1(d,J=3.7Hz,1H),6.47(d,J=3.7Hz,1H),3.79(s,6H),3.25(q,J=6.0Hz,2H),3.18(q,J=6.2Hz,2 H), 2.92-2.85 (m, 4H), 1.83 (q, J = 7.2Hz, 2H), 1.67 (dd, J = 14.1, 8.5Hz, 2H), 1.51 (q, J = 7.2Hz, 2H).
[0154] Example 3: Free radical scavenging effect of spermidine / spermine derivatives
[0155] 1.DPPH scavenging ability
[0156] (1) Reagent preparation: First dissolve the sample to be tested in DMSO, then dilute it with anhydrous methanol to 640μM, 160μM, 40μM and 10μM solutions. The blank group contains the same concentration of DMSO. Accurately weigh 6.4mg DPPH and add 8mL methanol. After fully dissolving, prepare a mother solution with a concentration of 2mM and store it in a refrigerator at 4℃ away from light. When used, dilute it with anhydrous methanol to a concentration of 100μM DPPH methanol solution for the experiment.
[0157] (2) Experimental method: 100 μL of sample solution of each concentration (sample group) or 100 μL of methanol (blank control group) was added to a 96-well plate, and then 100 μL of 100 μM DPPH methanol solution (final concentration was 50 μM) was quickly added. Three replicate wells were added for each sample concentration. After the solution was shaken evenly, it was placed in the dark at room temperature for one hour, and then its absorbance was measured at a wavelength of 517 nm on an ELISA reader. The DPPH clearance rate of the sample was calculated using the formula.
[0158] (3) Figure 1As shown, the following information was obtained: the scavenging rate of the parent nucleus Spd and Spm for DPPH free radicals was low with the increase of concentration, and our modification of them significantly improved the scavenging ability of free radicals. Except for the compound Spm-2, which had a low scavenging ability for DPPH at any concentration, the other compounds showed high scavenging ability for DPPH, most of which were stronger than Spd and Spm. In particular, Spd-5 achieved a scavenging efficiency of more than 80% at the lowest concentration of 3μM. At the same time, Spm-4, Spm-5, and Spm-6 also had a strong scavenging effect, with a scavenging rate of more than 60% at a concentration of 10μM. The scavenging activity of the products Spd-2, Spd-3, Spm-2, and Spm-3 after acetylation of coumaric acid and ferulic acid was weakened compared with the unacetylated products Spd-6, Spd-7, Spm-5, and Spm-6, but even compounds with phenolic hydroxyl structures can have good free radical scavenging ability after acetylation. Comparing the DPPH ability of Spd series derivatives and Spm series derivatives, at low concentrations, the scavenging ability of Spm series derivatives was significantly higher than that of Spd series derivatives.
[0159] From the above information, we know that phenolic hydroxyl is a very important functional group structure for scavenging DPPH, which can enhance its activity in scavenging DPPH. In addition, Spm has a longer carbon chain than Spd, so the longer carbon chain can enhance the activity of scavenging DPPH.
[0160] 2. Comparison of hydroxyl radical (·OH) scavenging ability by Fenton method
[0161] (1) Experimental method: The hydroxyl radical scavenging rate detection kit (Fenton colorimetric method) was used strictly according to the instructions to determine the free radical scavenging ability.
[0162] (2) Experimental results: As can be seen from the figure, Figure 2 As shown, the following information was obtained: Spd-4 had the strongest hydroxyl radical scavenging ability, with a 60% scavenging effect at 3 μM, followed by Spd-1 and Spm-7, with a scavenging effect of about 40% at 10 μM. The remaining compounds all showed scavenging ability for hydroxyl radicals, and were dose-dependent. At the same concentration, most compounds had stronger hydroxyl radical scavenging ability than Spd and Spm.
[0163] 3. Comparison of superoxide anion (O 2 ·- ) Clearing ability
[0164] (1) Experimental method: The superoxide anion scavenging ability test kit was operated strictly according to the instructions to determine the free radical scavenging ability.
[0165] (2) Experimental results: Figure 3 As shown in the figure, the scavenging ability of the parent nuclei Spd and Spm for superoxide anions is weak, and the scavenging efficiency does not increase significantly with the increase of concentration. After the structural modification of Spd and Spm, the scavenging ability of superoxide anions is significantly enhanced. Among them, at a low concentration of 30μM, Spd-6 has the strongest superoxide anion scavenging ability, reaching 60%, followed by Spd-5, Spd-7, Spm-5, and Spm-6, and the scavenging rate is above 50% at a concentration of 3-30μM. By comparing the scavenging ability of Spd series derivatives and Spm series derivatives, it is found that similar to the scavenging of DPPH free radicals, most Spm series derivatives have significantly higher scavenging ability than the Spd series at low concentrations. In the Spd series and Spm series, the acetylated products of coumaric acid and ferulic acid Spd-2, Spd-3, Spm-2, and Spm-3 have a weakened ability to scavenging superoxide anions compared to the unacetylated products Spd-6, Spd-7, Spm-5, and Spm-6.
[0166] 4. Neuroprotective activity of compounds on glutamate-stimulated HT22 and N2a cells
[0167] from Figure 4 (a) and (b) show that the synthesized compounds increased the cell viability of HT22 compared with the modeling group in the low concentration range (3-30μM) (p<0.05), indicating that the compounds have neuroprotective activity. Compared with the positive drugs donepezil and minocycline, the neuroprotective activity of most compounds is weaker than that of the positive control group, but Spd-4 has no significant difference in neuroprotective activity at a concentration of 30μM and the positive drug donepezil (ns). Spd-4 has the best neuroprotective activity, indicating that Spd-4 has good neuroprotective activity and can be further studied. The neuroprotective activity of Spd-6 and Spd-7 is second. From Figures (c) and (d), it can be seen that the synthesized compounds increased the cell viability of N2a in the low concentration range (3-30μM) compared with the modeling group (p<0.05), and the neuroprotective activity of Spd-4 has no significant difference in neuroprotective activity with the positive drug donepezil (ns). By comparing Figure a and Figure b horizontally, after the introduction of acetyl group, the neuroprotective activity of Spd-2 was weakened compared with Spd-5 (p<0.05), but its toxicity to cells at high concentrations (100-300μM) was weaker than Spd-5, indicating that the introduction of acetyl group will weaken the neuroprotective activity, but reduce the toxicity of the drug to the body (p<0.05). The same situation applies to other compounds.
[0168] 5. Anti-neuroinflammatory activity of compounds on LPS-induced BV2 cells
[0169] like Figure 5As shown in the results, after administration, all polyamine derivatives at concentrations above 10 μM can reduce the amount of NO released by BV2 induced by LPS (p<0.05), indicating that the synthesized compounds have preliminary anti-neuroinflammatory activity. At low concentrations (3-30 μM), Spm-1 has the best inhibitory effect on NO release, while Spd-2 and Spd-4 also have a good inhibitory effect on BV2 inflammation, and are concentration-dependent. It can be seen that the introduction of hydroxyl or acetyl groups on the benzene ring does not significantly inhibit the release of NO.
[0170] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A compound, which is a compound as shown in Formula I or Formula II, or a stereoisomer, a pharmaceutically acceptable salt, a solvate or a prodrug thereof of a compound as shown in Formula I or Formula II: Where R 1 Cinnamic acid, acetylated p-coumaric acid, acetylated ferulic acid, ligustrazine acid, R 2 Cinnamic acid, acetylated p-coumaric acid, acetylated ferulic acid, ligustrazine acid, among which R 1 and R 2 same.
2. The compound of formula I or formula II according to claim 1, Features: The R 1 is cinnamic acid, acetylated p-coumaric acid, acetylated ferulic acid, ligustrazic acid; the R 2 It is cinnamic acid, acetylated p-coumaric acid, acetylated ferulic acid, and ligustrazic acid.
3. The compound of formula I and formula II according to claim 2, Features: Where R 1 and R 2 The cinnamic acid, acetylated p-coumaric acid and acetylated ferulic acid are β-phenylacrylic acid derivatives, and ligustrazine acid is a pyrazine acid derivative.
4. The compound according to claim 3, which has the following structural formula:
5. A method for preparing the compound according to any one of claims 1 to 4, Features: The corresponding β-phenylacrylic acid derivatives and pyrazinoic acid derivatives are reacted with 2-mercaptothiazoline to generate an intermediate, and the intermediate can be selectively amidated with the primary amines of spermine and spermidine to finally obtain the final compound.
6. The method according to claim 5, It is characterized in that The reaction process is as follows:
7. The method according to claim 6, It is characterized in that The specific steps are as follows: (1) Dissolve p-coumaric acid / ferulic acid in 30 mL of acetic anhydride, add a catalytic amount of dimethylaminopyridine, and react at room temperature overnight. Monitor the reaction by TLC. After the reaction is complete, add 100 mL of water and stir for 2 h in an ice bath. A white solid precipitates. Place in a refrigerator overnight, filter, wash the filter cake with distilled water, and dry in a vacuum drying oven to obtain a white solid. Proceed directly to the next step without purification; (2) Dissolve TMP in 300 mL of water and add KMnO 4 , heated to 50°C, reacted for 10 hours. After the reaction was complete, cooled, extracted with ethyl acetate, the organic phase was discarded, the aqueous phase was adjusted to pH 3 with 10% hydrochloric acid, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain a yellow solid 3,5,6-trimethylpyrazine-2-carboxylic acid; (3) Weigh cinnamic acid / acetylated p-coumaric acid / acetylated ferulic acid / ligustrazine acid and 2-mercaptothiazoline and dissolve them in 50 mL of dry dichloromethane solution, stir evenly, add N-methylimidazole, and then slowly add N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate in batches, and react at room temperature overnight. Monitor the reaction by TLC. After the reaction is completed, wash with water, then wash twice with dilute acid solution, wash with saturated brine, dry with anhydrous sodium sulfate, filter, concentrate, and purify by column chromatography (petroleum ether: ethyl acetate = 2:1) to obtain a yellow-green solid compound. (4) Weigh an appropriate amount of spermidine / spermine and dissolve it in ultra-dry dichloromethane, stir evenly, slowly add the above 2-mercaptothiazolyl derivative dissolved in ultra-dry dichloromethane, react overnight, monitor the reaction by TLC, until the yellow-green color in the reaction solution turns colorless, and do not treat it. Add di-tert-butyl dicarbonate and triethylamine and react for 4 hours. After the reaction is completed, wash with dilute hydrochloric acid solution and saturated brine, dry with anhydrous sodium sulfate, and purify by column chromatography (dichloromethane: methanol = 50: 1) to obtain a white transparent oil. Dissolve the obtained white transparent oil in ultra-dry ethyl acetate, add 4M hydrogen chloride ethyl acetate solution under ice bath, react for 4 hours, and after monitoring the reaction completion by TLC, spin dry the solvent to obtain a white solid, add pure water to dissolve it, and then add NaHCO 3 The pH was adjusted to 8, the aqueous phase was extracted with dichloromethane, the organic phases were combined, and the solvent was spin-dried to obtain the target product.
8. A composition, Features: The composition comprises the compound according to any one of claims 1 to 5, the stereoisomer of the compound, the pharmaceutically acceptable salt of the compound or the solvate of the compound, and a pharmaceutically acceptable auxiliary agent, carrier or diluent.
9. The compound according to any one of claims 1 to 5, the stereoisomer of the compound, the pharmaceutically acceptable salt of the compound or the solvate of the compound, or claim 8, wherein the health product or medicine is used to prevent or treat diseases such as glutamate excitotoxicity, MEF2 dysfunction, diseases related to oxidative stress damage free radicals, neurodegenerative diseases and glycolipid metabolic diseases.
10. The use of polyamine derivatives according to claim 9, wherein the diseases associated with oxidative stress damage or free radicals are: cerebral stroke, brain trauma, epilepsy, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Alzheimer's disease, hypoxia-ischemia, brain injury, cerebral hemorrhage, dementia, ischemic heart disease, vascular embolism, atherosclerosis, hypercholesterolemia, emphysema, cataract, diabetes, acute pancreatitis, alcohol-induced liver disease, and kidney damage.
11. The use of the polyamine derivatives according to claim 9, wherein the neurodegenerative disease is cerebral ischemia, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, ataxia-telangiectasia, bovine spongiform encephalopathy, Creutzfeldt-Jakob disease, Huntington's disease, cerebellar atrophy, multiple sclerosis, primary lateral sclerosis, or spinal muscular atrophy.
12. The use of polyamine derivatives according to claim 9, wherein the sugar and lipid metabolic disease is hyperlipidemia, diabetes, fatty liver, obesity, hypertension or cardiovascular and cerebrovascular diseases.
